DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION
The present invention relates to compositions and methods for treating and/or preventing heart failure with preserved ejection fraction (HFpEF), especially in subjects with an impaired NO-cGMP-PKG signalling axis. The inventors established that not all patients with clinically defined HFpEF suffer from insufficient NO-cGMP- PKG signalling. In accordance with the invention, patients with an HFpEF diagnosis can be selected/stratified based on biomarkers such as NADPH oxidase Type 5 (Nox5) plasma levels, nitration of tyrosine residues on plasma proteins and/or cell- based assays. Moreover, the inventors have found that treating this signalling network at two or more nodes, especially sGC and NO synthase, achieves the first-in-class mechanism-based, causal and high precision therapy for HFpEF endotype which is defined by insufficient NO-cGMP-PKG signalling..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Europäisches Patentamt - (2023) vom: 26. Okt. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
SCHMIDT HARALD HORST HEINZ WILHELM [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-10-26, Last update posted on www.tib.eu: 2023-11-17, Last updated: 2023-11-24 |
---|
Patentnummer: |
WO2023204698 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA018406742 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA018406742 | ||
003 | DE-627 | ||
005 | 20231124094931.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231110s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA018406742 | ||
035 | |a (EPA)WO2023204698 | ||
035 | |a (EPA)83081815 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a SCHMIDT HARALD HORST HEINZ WILHELM |e verfasserin |4 aut | |
245 | 1 | 0 | |a DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2023-10-26, Last update posted on www.tib.eu: 2023-11-17, Last updated: 2023-11-24 | ||
520 | |a The present invention relates to compositions and methods for treating and/or preventing heart failure with preserved ejection fraction (HFpEF), especially in subjects with an impaired NO-cGMP-PKG signalling axis. The inventors established that not all patients with clinically defined HFpEF suffer from insufficient NO-cGMP- PKG signalling. In accordance with the invention, patients with an HFpEF diagnosis can be selected/stratified based on biomarkers such as NADPH oxidase Type 5 (Nox5) plasma levels, nitration of tyrosine residues on plasma proteins and/or cell- based assays. Moreover, the inventors have found that treating this signalling network at two or more nodes, especially sGC and NO synthase, achieves the first-in-class mechanism-based, causal and high precision therapy for HFpEF endotype which is defined by insufficient NO-cGMP-PKG signalling. | ||
650 | 4 | |a tec | |
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a CALVO CRISTIAN NOGALES |4 aut | |
700 | 0 | |a PETRAINA ALEXANDRA |4 aut | |
700 | 0 | |a KNÖPP KAI |4 aut | |
700 | 0 | |a MUCKE HERMANN ALOIS MARTIN |4 aut | |
700 | 0 | |a SEDDING DANIEL GERHARD FRANZISKUS |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 26. Okt. |
773 | 1 | 8 | |g year:2023 |g day:26 |g month:10 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/83081815/publication/WO2023204698A1?q=WO2023204698 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
936 | u | w | |j 2023 |b 26 |c 10 |
951 | |a AR | ||
952 | |j 2023 |b 26 |c 10 |